Newsroom | 5735 results
Sorted by: Latest
-
Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL. The Tweed brand relaunch – now powered...
-
Phoenix and Raven Offer Eligible Canadians Ozempic® at the Same Price as Generic Semaglutide
TORONTO--(BUSINESS WIRE)--Phoenix and Raven offer eligible Canadians Ozempic® at the same starting price at $124.99 as generic semaglutide....
-
Lifechanging Dehp® High Treatment Presented at the 37th Annual Boston Trauma Conference
BOSTON--(BUSINESS WIRE)--Go dēhp® and dēhp® Theraputic CEO Josette Sullins and Dr. Maria Navarro DBH, LPC, TAD, EMDR-C, Chief Behavioral Health Officer and Clinical Director of Go dēhp® and dēhp® Theraputic, are showcasing their proprietary Dehp® High treatment Friday, May 29, 2026, at the 37th Annual Boston International Trauma Conference. Attendees of the sponsored dēhp Therapeutic Lunch and Learn during the conference will receive an introductory overview of the dIT and explore the stages of...
-
New Research Shows RADIESSE® Supports Substantial Regeneration of Collagen and Key Extracellular Matrix Proteins
RALEIGH, N.C.--(BUSINESS WIRE)--Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the publication of new research demonstrating that RADIESSE stimulates collagen production as well as other key components of the skin’s extracellular matrix (ECM) to support skin regeneration. The findings also show that RADIESSE improves signs of solar elastosis, a significant component of sun damage in skin. Published in the Journal of Cosmetic Dermatology, the six-mont...
-
Retension Pharmaceuticals Appoints Alison Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer
FALLS CHURCH, Va.--(BUSINESS WIRE)--Retension appoints Alison D. Schecter as CMO and Alex Schwartz as CFO as RTN-001 advances in a Phase 2b trial in hypertension....
-
HAYA Therapeutics annonce l’administration du traitement à la première cohorte dans le cadre de l’essai clinique de phase 1 sur HTX-001, un traitement expérimental de précision visant la reprogrammation cellulaire destiné à la fibrose cardiaque
LAUSANNE, Suisse et SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics SA, une société de biotechnologie de précision de stade clinique qui développe des thérapies innovantes, programmables et guidées par l’ARN ciblant le génome régulateur afin de reprogrammer les états cellulaires pathologiques dans les maladies courantes, chroniques et liées à l’âge, a annoncé que la première cohorte avait été recrutée et avait reçu une première administration dans le cadre de l’essai clinique de phase 1 mené par...
-
HAYA Therapeutics gibt Dosierung der ersten Kohorte in Phase-1-Studie zu HTX-001 bekannt, einem Prüfpräparat zur gezielten zellulären Reprogrammierung bei Herzfibrose
LAUSANNE, Schweiz, und SAN DIEGO, Kalifornien, USA--(BUSINESS WIRE)--HAYA Therapeutics SA, ein klinisches Biotech-Unternehmen und Wegbereiter im Bereich präzisionsmedizinischer RNA-geführter Therapeutika, gab heute bekannt, dass die erste Kohorte in der klinischen Phase-1-Studie des Unternehmens zur Untersuchung von HTX-001 vollständig aufgenommen und dosiert wurde. Die Therapeutika von HAYA zielen auf das regulatorische Genom ab, um krankheitsfördernde Zellzustände bei häufigen, chronischen un...
-
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001, an Investigational Precision Cellular Reprogramming Therapy for Cardiac Fibrosis
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Trial of HTX-001, an Investigational Cellular Reprogramming Therapy for Cardiac Fibrosis...
-
SERI Lugano startet internationale wissenschaftliche Initiative zur Förderung der Forschung im Bereich lichtbasierter Neurowissenschaften und der Zirbeldrüsenforschung
LUGANO, Schweiz--(BUSINESS WIRE)--Da das wissenschaftliche Interesse an lichtbasierter Stimulation, neuroendokriner Regulation und integrativer Medizin international weiter zunimmt, hat das Switzerland Eye Research Institute (SERI Lugano) eine neue internationale wissenschaftliche Outreach-Initiative ins Leben gerufen, die sich auf die Einbindung der Öffentlichkeit und die interdisziplinäre Forschungskommunikation in den Bereichen Neurowissenschaften und zelluläre Modulation konzentriert. Die I...
-
Riassunto: SERI Lugano lancia l'iniziativa International Scientific Outreach sulla ricerca neuroscientifica e sulla ghiandola pineale basata sulla luce
LUGANO, Svizzera--(BUSINESS WIRE)--Mentre aumenta a livello internazionale l'interesse scientifico per la stimolazione basata sulla luce, la regolazione neuroendocrina e la medicina integrativa, lo Switzerland Eye Research Institute (SERI Lugano) ha lanciato una nuova iniziativa scientifica internazionale incentrata sul coinvolgimento del pubblico e sulla comunicazione interdisciplinare nel settore delle neuroscienze e della modulazione cellulare. L'iniziativa mira a promuovere la più ampia com...
